Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1-47. (cancelled)

48. (new) A method of inhibiting C-fibre neuron activity, comprising administering to a patient a first lectin in a amount effective to inhibit C-fibre neuron activity, wherein the first lectin is selected from the group consisting of a lectin that binds to a galactosyl residue, and a lectin that binds to a glucosyl residue.

49. (new) A method according to Claim 48, wherein the method is for treating a disease or condition resulting from the stimulation of C-fibre neuron activity.

50. (new) A method according to Claim 49, wherein the disease or condition is selected from the group consisting of pain, psoriasis, inflammation, and mucus hypersecretion.

51. (new) A method according to claim 48, wherein said lectin is an *Erythrina cristagalli* lectin.

52. (new) A method of stimulating C-fibre neuron activity, comprising administering to a patient a first lectin in an amount effective to stimulate C-fibre neuron

activity, wherein the first lectin is selected from the group consisting of a lectin that binds to a galactosyl residue, and a lectin that binds to a glucosyl residue.

53. (new) A method according to claim 52, wherein said lectin is an *Erythrina cristagalli* lectin.

54. (new) A method of inhibiting C-fibre neuron activity, comprising administering to a patient a first lectin coupled to a peptide or protein, wherein the first lectin coupled to the peptide or protein is present in an amount effective to inhibit C-fibre neuron activity, wherein the first lectin is selected from the group consisting of a lectin that binds to a galactosyl residue, and a lectin that binds to a glucosyl residue, and wherein the peptide or protein substantially lacks clostridial neurotoxin endopeptidase enzyme activity.

55. (new) A method according to Claim 54, wherein the peptide or protein is an endopeptidase that substantially lacks clostridial neurotoxin endopeptidase enzyme activity.

56. (new) A method according to Claim 55, wherein the peptide or protein is an LH_N fragment of a clostridial neurotoxin that substantially lacks clostridial neurotoxin endopeptidase activity.

57. (new) A method according to Claim 54, wherein the method is for treating a disease or condition resulting from the stimulation of C-fibre neuron activity.

58. (new) A method according to Claim 57, wherein the disease or condition is selected from the group consisting of pain, psoriasis, inflammation, and mucus hypersecretion.

59. (new) A method according to claim 54, wherein said lectin is an *Erythrina cristagalli* lectin.

60. (new) A method of stimulating C-fibre neuron activity, comprising administering to a patient a first lectin coupled to a peptide or protein, wherein the first lectin coupled to the peptide is present in an amount effective to inhibit C-fibre neuron activity, wherein the first lectin is selected from the group consisting of a lectin that binds to a galactosyl residue, and a lectin that binds to a glucosyl residue, and wherein the peptide or protein substantially lacks clostridial neurotoxin endopeptidase enzyme activity.

61. (new) A method according to claim 60, wherein said lectin is an *Erythrina cristagalli* lectin.